Waters said it is furnishing an investor presentation (Exhibit 99.1) that it will present at the J.P. Morgan Healthcare Conference on January 12, 2026 to Item 7.01 on Form 8-K.

1. 01

   Waters said it is furnishing an investor presentation (Exhibit 99.1) that it will present at the J.P. Morgan Healthcare Conference on January 12, 2026 to Item 7.01 on Form 8-K.

2. 02

   The company said that in connection with the proposed transaction with Augusta SpinCo and Becton, Dickinson and Company (BD), Form S-4 was declared effective by the SEC on December 23, 2025 and Form 10 was declared effective on December 31, 2025. It said the definitive proxy statement/prospectus was mailed on or about December 23, 2025 to shareholders of record as of December 19, 2025.

3. 03

   Waters presented the FY-25 GAAP revenue of BD's Biosciences and Diagnostic Solutions businesses at $3.3B and disclosed management estimates of total cost synergies of $200M and year 5 revenue synergy targets of $290M ($145M in adjusted EBITDA).

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call. Some paragraphs were omitted because their support in the source could not be confirmed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.